UnknownNCT06026644
Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Principal Investigator
- Alice Di RoccoAou Policlinico Umberto I - Dipartimento Di Medicina Traslazionale - Sezione Ematologia
- Enrollment
- 170 enrolled
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2022 – 2026
Study locations (13)
- Aou Di Bologna - Policlinico S. Orsola-malpighi - Uoc Ematologia, Bologna, Italy
- Asst Degli Spedali Civili Di Brescia - Ssvd Centro Trapianti Midollo Per Adulti - Cattedra Di Ematologia, Brescia, Italy
- AOU Careggi - SOD terapie cellulari e Medicina Trasfusionale, Florence, Italy
- Irccs Aou San Martino - Genova - Uo Ematologia E Trapianti, Genova, Italy
- Fondazione Irccs "Istituto Nazionale Tumori" - Milano - Sc Ematologia, Milan, Italy
- Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Ad Indirizzo Oncologico, Palermo, Italy
- Asl Pescara, Presidio Ospedaliero 'Spirito Santo' - Uoc Ematologia Clinica, Pescara, Italy
- Aou Pisana - Uo Ematologia Universitaria, Pisa, Italy
- Aou Policlinico Umberto I - Dipartimento Di Medicina Traslazionale - Sezione Ematologia, Roma, Italy
- Ististuto Clinico Humanitas - Rozzano - Uo Oncologia Medica Ed Ematologia, Rozzano, Italy
- Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia - Università Degli Studi Di Torino, Torino, Italy
- Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2, Torino, Italy
- Aulss 8 Berica - Ospedale Di Vicenza - Uoc Ematologia, Vicenza, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06026644 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic